DoD P&T Committee- Future Meetings of the DoD P&T Committee

The Department of Defense (DoD) Pharmacy & Therapeutics (P&T) Committee's mission is to uniformly, consistently, and equitably provide appropriate drug therapy to meet the clinical needs of DoD beneficiaries in an effective, efficient, and fiscally responsible manner. Minutes of DoD P&T Committee meetings and the Committee's charter are available on the DoD P&T Committee homepage on the TRICARE Pharmacy website.

Guidance for DoD P&T Committee member's Interaction with Industry

Click here to go to the Uniform Formulary Beneficiary Advisory Panel (BAP) homepage.

Uniform Formulary Therapeutic Conversion Example

All meetings 1998-2006 click here

2007 P&T Committee Page | 2008 P&T Committee Page | 2011 P&T Committee Page | 2012 P&T Committee Page | 2013 P&T Committee Page | 2014 P&T Committee Page



2015 DoD P&T Committee Meeting Schedule


* In the event the class of drugs specified herein has previously been reviewed, the government solicits quotes for new BPAs/VARRs to replace any existing BPAs/VARRs . The government will not consider existing BPA/VARR prices in the UF evaluation. Any existing BPA/VARR for this class of drugs will be terminated upon the conclusion of the UF decision.


Meeting Date
(click on date)
Review Type Drug Classes/New Drugs Under Review* / Information for Manufacturers**
Meeting Window for Manufacturers to give Clinical/Cost Presentations
Feb 2015 Class Review ORAL ONCOLOGICAL AGENTS/PROSTATE I & II December 2014

BELSOMRA - Solicitation Cancelled
Class Review TRANSMUCOSAL IMMEDIATE RELEASE FENTANYL
Class Review PULMONARY ARTERIAL HYPERTENSION AGENTS
Designated Newly Approved Drugs ZONTIVITY, HETLIOZ, BELSOMRA, JARDIANCE, ESOMEPRAZOLE STRONTIUM, STENDRA
May 2015 Class Review NEWER ORAL ANTICOAGULANTS AND WARFARIN March 2015
Class Review HEPATITIS ANTIVIRALS (HEPATITIS C)
Designated Newly Approved Drugs To Be Determined
Aug 2015 Class Review DIABETES NON-INSULIN (GLP-1 RECEPTOR AGONISTS) June 2015
Class Review DIABETES NON-INSULIN (SGLT-2 INHIBITORS)
Class Review NARCOTIC ANALGESICS
Class Review ONCOLOGICAL AGENTS - CML DRUGS
Designated Newly Approved Drugs To Be Determined
Nov 2015 Class Review ANTILIPIDEMICS-2 (FISH OILS) September 2015
Class Review PULMONARY-2 AGENTS (COPD)
Class Review SEIZURE MEDICATIONS
Class Review ACNE - ISOTRETINOIN
Class Review CONTRACEPTIVE AGENTS (MULTIPHASIC & CHEWABLE)
Designated Newly Approved Drugs To Be Determined


Subject to Change Disclaimer

The Defense Health Agency reserves the right to change the classes, subclasses and/or designated new drugs, and other requirements, of whatever kind, affecting solicitations. The provisions of this table do not constitute a contract, express or implied, between the Defense Health Agency and manufacturer or eligible bidder.

*/** If the DoD P&T Committee is unable to complete an evaluation of any of the drug classes, the Committee will continue its efforts at the next meeting.

POD Webmaster
Last updated 1/13/15

Back To Top
WARNING: Unauthorized attempts to upload information or change information on this service are strictly prohibited and may be punishable under the Computer
Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act. A Division of the Pharmaceutical Operations Directorate.